SIDEROSENSE Siderophore-mediated delivery of antibacterial antisense agents
- Coordinator
- Stichting Radboud Universiteit, Netherlands
- Runs
- 1 December 2026 to 31 May 2028
- Status
- Running
- EU funding
- €150k
- Total cost
- —
- Partners
- 1 organisations in 1 countries
- Type
- European Research Council grant
- Grant agreement
- 101334519
What the project is doing
In the project's own words, from its summary on CORDIS.
Antibacterial resistance represents a major and growing threat to global public health, while the development of new antibiotics with novel mechanisms of action has largely stagnated. The SIDEROSENSE project addresses this challenge by advancing a fundamentally new antibacterial modality based on antisense technology. SIDEROSENSE enables selective intracellular delivery of antibacterial antisense oligonucleotides, overcoming a long-standing barrier to the clinical translation of antisense-based antibacterials.
Proof-of-principle studies have demonstrated potent antibacterial activity. This ERC Proof of Concept project aims to establish whether the SIDEROSENSE technology translates into a safe and effective antibacterial strategy. The project will generate critical experimental data, while simultaneously strengthening the IP position and assessing regulatory and commercial pathways. In parallel, a market and exploitation strategy will be developed to support informed go/no-go decisions and downstream translation.
SIDEROSENSE will deliver the essential technical and strategic validation required to assess the feasibility of antisense-based antibiotics as a new therapeutic class and to position the technology for subsequent translational funding and clinical development.
Topics
Who is involved
| Organisation | City | Country | Role |
|---|---|---|---|
| Stichting Radboud Universiteit | Nijmegen | Netherlands | Coordinator |
Source: CORDIS, European Commission. Data of 5 Nov 2026, reused under the Commission's reuse policy. View on CORDIS · Grant DOI